Growth assessment parameters before and after biological treatment in the different studies. by Yasmine Makhlouf (17409866)

Subjects:

Mean scores and 95% CI of mental health symptoms, COVID-19 admissions and effect size during follow-up. by A. H. Ayesha Lavell (16734002)

Effect of ex vivo treatment with rhTGFβ1 or a TGFβ1 inhibitor on monocyte responses to rgE stimulation. Monocytes and NK cells purified from PBMC collected from 10 RZV recipients (demographics in S4 Table) before vaccination (D0) and 90 days post-vaccination (D90) were combined ex vivo and stimulated with VZV-rgE. A subset of D0 monocyte & NK cocultures was also treated with the TGFβ1 inhibitor LY (D0 LY), and a subset of D90 cocultures were supplemented with rhTGFβ1. The graph shows individual data points, means and p values calculated by Friedman test for repeated measures with FDR correction. LY treatment of cells collected on D0 significantly increased their activation to levels similar to D90. Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0. by Michael J. Johnson (5818168)

“…Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0.…”

Clade body sizes using log transformed mean adult size to represent each turritellid and tegulid species’ size, and typical size to represent the size of each species belonging to... by Brendan M. Anderson (11234356)

Differences in growth, metabolism and migration of BY-02 cells compared with WT cells. by Jiahao Zheng (807470)

The targeting strategies, qRT-PCR, and western bolt to verify BY-02 cells. by Jiahao Zheng (807470)

Mean GHQ scores (2019- September 2021). by Mhairi Webster (20454888)

Flow chart of experimental protocol. by Eun-Seon Yang (19751340)

“…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”

A representative ultrasound axis image. by Eun-Seon Yang (19751340)

“…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”

Table 1_Elevated CO2 decreases micronutrient Zn but not Fe in vegetables – evidence from a meta-analysis.docx by Xiaolin Wang (303612)

Reducing Dscam1 diversity decreases adult lifespan in a cluster-specific manner, also see S6 and S7 Figs. by Haiyang Dong (4783608)

Table 1_Fertilization decreases the effect of ammonium nitrogen on microorganisms in Chinese Carex tibetikobresia meadows during rest-grazing.docx by Xuanbo Zhou (19374205)

Table 1_Subjective spatial orientation discomfort is associated with decreased real-world spatial performance and lower cognitive function.docx by Johannes Gerb (10287758)

Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

“…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”

Data Sheet 1_A synonymous mutation of rs1137070 cause the mice Maoa gene transcription and translation to decrease.pdf by Kai Xin Li (19696741)

Data Sheet 1_Dihydroartemisinin decreases pre-existing neutralizing antibodies against adeno-associated virus in challenged mice.pdf by Jingjing Fang (124938)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

FGF18 injections increase TIMP1 and decrease MMP13 and NOGGIN, suggesting healing of degeneration induction of anabolic effect. by Flavia Gomes Velasque Gama (21175112)